×
About 2,089 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  1,021 results

Rituximab-induced Hypogammaglobulinemia and Infection Risk in Pediatric Patients.
https://doi.org/10.1016/j.jaci.2021.03.041
The Journal of Allergy and Clinical Immunology; Labrosse R, Barmettler S et. al.

Apr 16th, 2021 - Rituximab (RTX) is a B-cell depleting agent used in B-cell malignancies and autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic hypogammaglobulinemia following RTX. However, this phenomenon has not been well delin...

A Novel Homozygous TRNT1 Mutation in a Child With an Early Diagnosis of Common Variable...
https://doi.org/10.1097/MPH.0000000000002101
Journal of Pediatric Hematology/oncology; Topyildiz E, Edeer Karaca N et. al.

Apr 12th, 2021 - Although sideroblastic anemias (SAs) may be associated with different etiologies, deterioration of mitochondrial heme biosynthesis in bone marrow erythroid cells is a general abnormality. Congenital SA associated with immunodeficiency, periodic fe...

Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019084
Rheumatology International; Wade SD, Kyttaris VC

Apr 3rd, 2021 - B-cell targeted therapies, such as rituximab (RTX), are used widely in autoimmune rheumatic diseases (AIRD). RTX can cause hypogammaglobulinemia and predispose patients to infections. Herein, we asked whether the underlying diagnosis influences th...

Immunoglobulin G: A useful outcome marker in the follow-up of cystic fibrosis patients?
https://doi.org/10.1002/iid3.426
Immunity, Inflammation and Disease; Hanssens LS, Cellauro S et. al.

Mar 30th, 2021 - Hypergammaglobulinemia (hyper-IgG) and hypogammaglobulinemia (hypo-IgG) have been reported in patients with cystic fibrosis (CF). Although the clinical respiratory course is paradoxically different, depending on the IgG status, this association re...

Immunoglobulin levels in systemic lupus erythematosus: A narrative review.
https://doi.org/10.1177/09612033211004714
Lupus Almaghlouth I, Johnson SR et. al.

Mar 29th, 2021 - Immunoglobulins play a fundamental role in the protection of the human body against internal and external threats. They also contribute to the immune system homeostasis and maintenance of self-tolerance. Hypogammaglobulinemia is occasionally encou...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,041 results

Risk for Hypogammaglobulinemia, Infections With Rituximab Increased in Pediatric Patients
https://www.medscape.com/viewarticle/949577

Apr 19th, 2021 - A quarter of children receiving treatment with rituximab developed hypogammaglobulinemia within 18 months of starting the drug, according to preliminary research shared at the annual scientific meeting of the Childhood Arthritis and Rheumatology R...

Rituximab-induced Hypogammaglobulinemia and Infection Risk in Pediatric Patients.
https://doi.org/10.1016/j.jaci.2021.03.041
The Journal of Allergy and Clinical Immunology; Labrosse R, Barmettler S et. al.

Apr 16th, 2021 - Rituximab (RTX) is a B-cell depleting agent used in B-cell malignancies and autoimmune diseases. A subset of adult patients may develop prolonged and symptomatic hypogammaglobulinemia following RTX. However, this phenomenon has not been well delin...

A Novel Homozygous TRNT1 Mutation in a Child With an Early Diagnosis of Common Variable...
https://doi.org/10.1097/MPH.0000000000002101
Journal of Pediatric Hematology/oncology; Topyildiz E, Edeer Karaca N et. al.

Apr 12th, 2021 - Although sideroblastic anemias (SAs) may be associated with different etiologies, deterioration of mitochondrial heme biosynthesis in bone marrow erythroid cells is a general abnormality. Congenital SA associated with immunodeficiency, periodic fe...

Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019084
Rheumatology International; Wade SD, Kyttaris VC

Apr 3rd, 2021 - B-cell targeted therapies, such as rituximab (RTX), are used widely in autoimmune rheumatic diseases (AIRD). RTX can cause hypogammaglobulinemia and predispose patients to infections. Herein, we asked whether the underlying diagnosis influences th...

Immunoglobulin G: A useful outcome marker in the follow-up of cystic fibrosis patients?
https://doi.org/10.1002/iid3.426
Immunity, Inflammation and Disease; Hanssens LS, Cellauro S et. al.

Mar 30th, 2021 - Hypergammaglobulinemia (hyper-IgG) and hypogammaglobulinemia (hypo-IgG) have been reported in patients with cystic fibrosis (CF). Although the clinical respiratory course is paradoxically different, depending on the IgG status, this association re...

see more →

News  23 results

Risk for Hypogammaglobulinemia, Infections With Rituximab Increased in Pediatric Patients
https://www.medscape.com/viewarticle/949577

Apr 19th, 2021 - A quarter of children receiving treatment with rituximab developed hypogammaglobulinemia within 18 months of starting the drug, according to preliminary research shared at the annual scientific meeting of the Childhood Arthritis and Rheumatology R...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.staging.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents
https://www.mdedge.com/multiplesclerosishub/article/209320/multiple-sclerosis/hypogammaglobulinemia-and-infection-risk/page/0/1

Oct 2nd, 2019 - Ocrelizumab Tobias Derfuss, MD, provided data on infection rates in the pivotal phase 3 OPERA and ORATIO double-blind clinical trials combined with their long-term, open-label extensions totaling 288 weeks, or nearly 6 years, of follow-up. Serum I.

Plerixafor produced dramatic responses in severe WHIM syndrome
https://www.mdedge.com/familymedicine/article/192393/anemia/plerixafor-produced-dramatic-responses-severe-whim-syndrome
MDedge Hematology and Oncology; Amy Karon

Jan 9th, 2019 - Low-dose treatment with plerixafor, a CXC chemokine receptor 4 antagonist, was well tolerated and markedly improved severe presentations of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome in three patients who could not.

see more →